Australia’s medicines regulator has issued a serious warning after a patient suffered a torn oesophagus following the use of a counterfeit weight-loss peptide product purchased outside approved medical channels.
The incident has raised fresh concerns about the growing market for unregulated peptide drugs promoted online.
What happened
According to Australia’s Therapeutic Goods Administration (TGA), a patient experienced:
- Severe and uncontrollable vomiting
- A ruptured oesophagus (a potentially life-threatening injury)
- Hospital treatment following the reaction
The patient had taken what they believed was retatrutide, an experimental weight-loss peptide.
What the product actually contained
After testing the seized sample, regulators found:
- The product did not contain retatrutide
- It contained semaglutide instead
- The dose was approximately 8 times higher than approved semaglutide products
This mismatch raised concerns about counterfeit manufacturing and unsafe dosing.
What is retatrutide?
Retatrutide is a type of drug known as a peptide, which works by mimicking hormones involved in hunger and metabolism.
However:
- It is not approved in Australia
- It is not approved by major global regulators
- It cannot be legally prescribed or sold in the country
Despite this, it has been widely promoted online under names like:
- Retatrutide
- Reta
- R-10
- R-20
Often, these are sold in unlabelled vials through unofficial channels.
Why regulators are concerned
Officials say the biggest risks with these products are:
- No guarantee of what is inside the vial
- Unknown or incorrect dosage
- Possible contamination or lack of sterility
- Risk of toxins or unknown substances
The Therapeutic Goods Administration warned that injectable products are especially dangerous because:
- Improper manufacturing can cause infections
- Contaminants can trigger severe immune reactions
- Users may inject incorrect or unsafe doses
Reported health risks
Authorities have already linked unapproved peptides to multiple serious cases, including:
- Acute liver toxicity
- Severe allergic reactions
- Inflammation-related complications
A recent warning from Australian health authorities also followed six cases of liver injury linked to products labelled as retatrutide.
Why this is happening
Experts say demand is being driven by:
- Rapid popularity of weight-loss peptides
- Social media promotion
- Online wellness clinics and unregulated sellers
- Easy access to “research” chemicals marketed as lifestyle drugs
This has created a growing grey market where medical oversight is often missing.
Official response
Australian regulators stress that:
- Only approved medicines meet strict safety and quality standards
- Illegal imports are not tested or controlled
- Self-injection increases risk of dosing errors and serious harm
Health officials are urging the public to avoid unapproved peptide products entirely.
Bigger picture
This case highlights a wider global issue: as peptide-based weight-loss drugs become more popular, counterfeit and unregulated versions are also spreading quickly online — often with dangerous or unknown contents.